Advanced search
Publication Cover
Pharmacogenomics Volume 13, 2012 - Issue 1
Submit an article Journal homepage
442
Views
0
CrossRef citations to date
0
Altmetric
Perspective

Pharmacogenetics of Drug-Metabolizing Enzymes: The Prodrug Hypothesis

Evan J Begg1 Department of Medicine, University of Otago – Christchurch, Christchurch 8140, New ZealandCorrespondence[email protected]
,
Nuala A Helsby2 School of Medical Sciences, University of Auckland, Auckland, New Zealand
&
Berit P Jensen1 Department of Medicine, University of Otago – Christchurch, Christchurch 8140, New Zealand
Pages 83-89 | Published online: 19 Dec 2011

References

  • Laing RE , HessP, ShenY, WangJ, HuSX. The role and impact of SNPs in pharmacogenetics and personalized medicine. Curr. Drug Metab.12 , 460–486 (2011).
  • Gardiner SJ , BeggEJ. Pharmacogenetics, drug-metabolising enzymes, and clinical practice. Pharmacol. Rev.58 , 521–590 (2006).
  • Flockhart DA , SkaarT, BerlinDS, KleinTE, NguyenAT. Clinically available pharmacogenomics tests. Clin. Pharmacol. Ther.86 , 109–113 (2009).
  • Becquemont L , AlfirevicA, AmstutzU et al. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB conference on pharmacogenetics and pharmacogenomics. Pharmacogenomics 12 , 113–124 (2010).
  • Canterbury District Health Board. Preferred Medicines List, 15th Edition.The Caxton Press, Christchurch, New Zealand. ISBN 0-473-08171-7 (2011).
  • Zhou S . Clinical pharmacogenomics of thiopurine S-methyltransferase. Curr. Clin. Pharmacol.1 , 119–28 (2006).
  • Weinshilboum RM , SladekSL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet.32 , 651–662 (1980).
  • Roberts RL , GearryRB, KennedyMA, BarclayML. Beyond TPMY: genetic influences on thiopurine drug responses in inflammatory bowel disease. Per. Med.5(3) , 233–248 (2008).
  • Kaskas BA , LouisE, HindorfU et al. Safe treatment of thiopurine S-methyltransferase deficient Crohn‘s disease patients with azathioprine. Gut 52 , 140–142 (2003).
  • Gardiner SJ , GearryRB, BeggEJ, ZhangM, BarclayML. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold. Clin. Gastroenterol. Hepatol.6 , 654–660 (2008).
  • Gardiner SJ , BeggEJ. Pharmacogenetics testing for drug metabolizing enzymes – is it happening in practice? Pharmacogenet. Genomics15 , 365–369 (2005).
  • Schroth W , GoetzMP, HamannU et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 302 (13) , 1429–1436 (2009).
  • Mega JL , SimonT, ColletJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. JAMA 304(16) , 1821–1830 (2010).
  • Bouman HJ , SchomigE, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med.17 , 110–116 (2011).
  • Marsh S , HoskinsLM. Irinotecan pharmacogenomics. Pharmacogenomics11(7) , 1003–1010 (2010).
  • Pirmohamed M . Warfarin: almost 60 years old and still causing problems. Br. J. Clin. Pharmacol.62(5) , 509–511 (2006).
  • The International Warfarin Pharmacogenomics Consortium; Klein TE, Altman RB et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med.360 , 753–764 (2009).
  • Marsh S . Thymidylate synthase pharmacogenetics. Invest. New Drugs23(6) , 533–537 (2005).
  • Thorn CF , MarshS, CarrilloMW, McLeodHL, KleinTE, AltmanRB. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet. Genomics21 , 237–242 (2011).
  • Helsby NA , HuiCY, GoldthorpeMA et al. The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. Br. J. Clin. Pharmacol. 70 , 844–53 (2010).
  • Ramanaiah TV , GajananaA. Superior antimalarial activity of proguanil to cycloguanil after in vitro bioconversion. Trans. R. Soc. Trop. Med. Hyg.82 , 358–359 (1988).
  • Herrlin K , MasseleAY, RimoyG et al. Slow chlorguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype. Clin. Pharmacol. Ther. 68 , 189–198 (2000).
  • Mallal S , PhillipsE, CarosiG et al. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med.358 , 568–579 (2008).
  • Dalen P , DahlML, Bernal Ruiz ML, Nordin J, Bertilsson L. 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes. Clin. Pharmacol. Ther.63 , 444–452 (1998).
  • Stamp L , RobertsR, KennedyM, BarclayM, O‘DonnellJ, ChapmanP. The use of low dose methotrexate in rheumatoid arthritis – are we entering a new era of therapeutic drug monitoring and pharmacogenomics? Biomed. Pharmacother.10 , 678–87 (2006).

▪ Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.